Effects of phosphodiesterase type 5 inhibition on systemic and pulmonary hemodynamics and ventricular function in patients with severe symptomatic aortic stenosis

Circulation

Volumn 125, Issue 19, 2012, Pages 2353-2362

  Lindman, Brian R ^a   Zajarias, Alan ^a   Madrazo, José A ^a   Shah, Jay ^a   Gage, Brian F ^a   Novak, Eric ^a   Johnson, Stephanie N ^a   Chakinala, Murali M ^a   Hohn, Tara A ^a   Saghir, Mohammed ^a   Mann, Douglas L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

aortic valve stenosis; heart failure; hemodynamics; hypertension, pulmonary; phosphodiesterase inhibitors

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL;

AGED; AORTA STENOSIS; ARTERIAL PRESSURE; ARTICLE; BLOOD VESSEL COMPLIANCE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ECHOCARDIOGRAPHY; FEMALE; HEART EJECTION FRACTION; HEART RATE; HEART STROKE VOLUME; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE FUNCTION; HUMAN; HYPOTENSION; LUNG EDEMA; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MALE; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY ARTERY OCCLUSION PRESSURE; RHINORRHEA; SINGLE DRUG DOSE; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; AORTIC VALVE STENOSIS; BLOOD PRESSURE; COMPLIANCE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; FEMALE; HUMANS; MALE; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PULMONARY CIRCULATION; PURINES; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; SULFONES; TREATMENT OUTCOME; VASCULAR RESISTANCE; VENTRICULAR FUNCTION, LEFT; VENTRICULAR FUNCTION, RIGHT;

EID: 84861228981     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.081125     Document Type: Article

References (42)

1. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O'Gara PT, O'Rourke RA, Otto CM, Shah PM, Shanewise JS. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2008;118: e523-e661.
2. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005;352:2389-2397. (Pubitemid 40958435)
3. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial. Circulation. 2010;121:306-314.
4. Otto CM. Valvular aortic stenosis: disease severity and timing of intervention. J Am Coll Cardiol. 2006;47:2141-2151. (Pubitemid 43795057)
5. Carabello BA, Paulus WJ. Aortic stenosis. Lancet. 2009;373:956-966.
6. Melby SJ, Moon MR, Lindman BR, Bailey MS, Hill LL, Damiano RJ Jr. Impact of pulmonary hypertension on outcomes after aortic valve replacement for aortic valve stenosis. J Thorac Cardiovasc Surg. 2011; 141:1424-1430.
7. Faggiano P, Antonini-Canterin F, Ribichini F, D'Aloia A, Ferrero V, Cervesato E, Pavan D, Burelli C, Nicolosi G. Pulmonary artery hypertension in adult patients with symptomatic valvular aortic stenosis. Am J Cardiol. 2000;85:204-208. (Pubitemid 30026103)
8. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54:S43-S54.
9. Pai RG, Varadarajan P, Kapoor N, Bansal RC. Aortic valve replacement improves survival in severe aortic stenosis associated with severe pulmonary hypertension. Ann Thorac Surg. 2007;84:80-85. (Pubitemid 46921129)
10. Mehta RH, Bruckman D, Das S, Tsai T, Russman P, Karavite D, Monaghan H, Sonnad S, Shea MJ, Eagle KA, Deeb GM. Implications of increased left ventricular mass index on in-hospital outcomes in patients undergoing aortic valve surgery. J Thorac Cardiovasc Surg. 2001;122: 919-928.
11. Lund O, Flo C, Jensen FT, Emmertsen K, Nielsen TT, Rasmussen BS, Hansen OK, Pilegaard HK, Kristensen LH. Left ventricular systolic and diastolic function in aortic stenosis: prognostic value after valve replacement and underlying mechanisms. Eur Heart J. 1997;18: 1977-1987. (Pubitemid 27526131)
12. Dweck MR, Joshi S, Murigu T, Alpendurada F, Jabbour A, Melina G, Banya W, Gulati A, Roussin I, Raza S, Prasad NA, Wage R, Quarto C, Angeloni E, Refice S, Sheppard M, Cook SA, Kilner PJ, Pennell DJ, Newby DE, Mohiaddin RH, Pepper J, Prasad SK. Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. J Am Coll Cardiol. 2011;58:1271-1279.
13. Di Eusanio M, Fortuna D, De Palma R, Dell'Amore A, Lamarra M, Contini GA, Gherli T, Gabbieri D, Ghidoni I, Cristell D, Zussa C, Pigini F, Pugliese P, Pacini D, Di Bartolomeo R. Aortic valve replacement: results and predictors of mortality from a contemporary series of 2256 patients. J Thorac Cardiovasc Surg. 2011;141:940-947.
14. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, Kass DA. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 2005;11:214-222. (Pubitemid 40321358)
15. Lepore JJ, Maroo A, Bigatello LM, Dec GW, Zapol WM, Bloch KD, Semigran MJ. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest. 2005;127:1647-1653. (Pubitemid 46218790)
16. Lewis GD, Lachmann J, Camuso J, Lepore JJ, Shin J, Martinovic ME, Systrom DM, Bloch KD, Semigran MJ. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation. 2007;115:59-66. (Pubitemid 46058612)
17. Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, Tawakol A, Gerszten RE, Systrom DM, Bloch KD, Semigran MJ. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation. 2007;116:1555-1562. (Pubitemid 47511419)
18. Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail. 2011;4:8-17.
19. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011;124: 164-174.
20. Tedford RJ, Hemnes AR, Russell SD, Wittstein IS, Mahmud M, Zaiman AL, Mathai SC, Thiemann DR, Hassoun PM, Girgis RE, Orens JB, Shah AS, Yuh D, Conte JV, Champion HC. PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. Circ Heart Fail. 2008;1:213-219.
21. Khot UN, Novaro GM, Popovic ZB, Mills RM, Thomas JD, Tuzcu EM, Hammer D, Nissen SE, Francis GS. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med. 2003;348:1756-1763. (Pubitemid 36514706)
22. Cramariuc D, Cioffi G, Rieck AE, Devereux RB, Staal EM, Ray S, Wachtell K, Gerdts E. Low-flow aortic stenosis in asymptomatic patients: valvular-arterial impedance and systolic function from the SEAS Substudy. J Am Coll Cardiol Cardiovasc Imaging. 2009;2:390-399.
23. Hachicha Z, Dumesnil JG, Pibarot P. Usefulness of the valvuloarterial impedance to predict adverse outcome in asymptomatic aortic stenosis. J Am Coll Cardiol. 2009;54:1003-1011.
24. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440-1463. (Pubitemid 41821197)
25. Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA, Nihoyannopoulos P, Otto CM, Quinones MA, Rakowski H, Stewart WJ, Waggoner A, Weissman NJ. Recommendations for evaluation of the severity of native valvular regurgitation with twodimensional and Doppler echocardiography. J Am Soc Echocardiogr. 2003;16:777-802. (Pubitemid 37391035)
26. Lindman BR, Arnold SV, Madrazo JA, Zajarias A, Johnson SN, Perez JE, Mann DL. The adverse impact of diabetes mellitus on left ventricular remodeling and function in patients with severe aortic stenosis. Circ Heart Fail. 2011;4:286-292.
27. de Simone G, Devereux RB, Roman MJ, Ganau A, Saba PS, Alderman MH, Laragh JH. Assessment of left ventricular function by the midwall fractional shortening/end-systolic stress relation in human hypertension. J Am Coll Cardiol. 1994;23:1444-1451. (Pubitemid 24158016)
28. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, Solomon SD, Louie EK, Schiller NB. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010;23:685-713.
29. Shmuylovich L, Kovacs SJ. Load-independent index of diastolic filling: model-based derivation with in vivo validation in control and diastolic dysfunction subjects. J Appl Physiol. 2006;101:92-101. (Pubitemid 44035353)
30. Shmuylovich L, Kovacs SJ. E-wave deceleration time may not provide an accurate determination of LV chamber stiffness if LV relaxation/viscoelasticity is unknown. Am J Physiol Heart Circ Physiol. 2007;292: H2712-H2720. (Pubitemid 47084519)
31. Kovacs SJ Jr, Barzilai B, Perez JE. Evaluation of diastolic function with Doppler echocardiography: the PDF formalism. Am J Physiol. 1987; 252(1)(pt 2):H178-H187.
32. Cohn JN, Franciosa JA. Vasodilator therapy of cardiac failure (second of two parts). N Engl J Med. 1977;297:254-258. (Pubitemid 8155008)
33. Briand M, Dumesnil JG, Kadem L, Tongue AG, Rieu R, Garcia D, Pibarot P. Reduced systemic arterial compliance impacts significantly on left ventricular afterload and function in aortic stenosis: implications for diagnosis and treatment. J Am Coll Cardiol. 2005;46:291-298. (Pubitemid 40966858)
34. Haddad F, Denault AY, Couture P, Cartier R, Pellerin M, Levesque S, Lambert J, Tardif JC. Right ventricular myocardial performance index predicts perioperative mortality or circulatory failure in high-risk valvular surgery. J Am Soc Echocardiogr. 2007;20:1065-1072. (Pubitemid 47321072)
35. Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, St Aubin C, Webster L, Rebeyka IM, Ross DB, Light PE, Dyck JR, Michelakis ED. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation. 2007;116:238-248. (Pubitemid 47196559)
36. Melenovsky V, Al-Hiti H, Kazdova L, Jabor A, Syrovatka P, Malek I, Kettner J, Kautzner J. Transpulmonary B-type natriuretic peptide uptake and cyclic guanosine monophosphate release in heart failure and pulmonary hypertension: the effects of sildenafil. J Am Coll Cardiol. 2009;54: 595-600.
37. Mahapatra S, Nishimura RA, Sorajja P, Cha S, McGoon MD. Relationship of pulmonary arterial capacitance and mortality in idiopathic pulmonary arterial hypertension. J Am Coll Cardiol. 2006;47:799-803. (Pubitemid 43243104)
38. Bach DS, Siao D, Girard SE, Duvernoy C, McCallister BD Jr, Gualano SK. Evaluation of patients with severe symptomatic aortic stenosis who do not undergo aortic valve replacement: the potential role of subjectively overestimated operative risk. Circ Cardiovasc Qual Outcomes. 2009;2: 533-539.
39. Weidemann F, Herrmann S, Stork S, Niemann M, Frantz S, Lange V, Beer M, Gattenlohner S, Voelker W, Ertl G, Strotmann JM. Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. Circulation. 2009;120:577-584.
40. Lund O, Kristensen LH, Baandrup U, Hansen OK, Nielsen TT, Emmertsen K, Jensen FT, Flo C, Rasmussen BS, Pilegaard HK. Myocardial structure as a determinant of pre-and postoperative ventricular function and long-term prognosis after valve replacement for aortic stenosis. Eur Heart J. 1998;19:1099-1108. (Pubitemid 28321391)
41. Lund O, Emmertsen K, Dorup I, Jensen FT, Flo C. Regression of left ventricular hypertrophy during 10 years after valve replacement for aortic stenosis is related to the preoperative risk profile. Eur Heart J. 2003;24: 1437-1446. (Pubitemid 36961834)
42. Herrmann HC, Chang G, Klugherz BD, Mahoney PD. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med. 2000;342:1622-1626. (Pubitemid 30341530)